PITTSBORO, NC -- (MARKET WIRE) -- February 13, 2007 -- Biolex Therapeutics today announced that its technology for optimizing monoclonal antibodies will be featured at the "Next Generation Antibodies and Antibody Technologies" session at the 9th Annual BIO CEO & Investor Conference. David Spencer, Ph.D., Biolex's Chief Operating Officer and Senior Vice President, Research and Development, will highlight the ability of the Company's LEX System(SM) to increase the efficacy and potency of monoclonal antibodies. The antibody session will take place at 9:00 a.m. EST on Wednesday, February 14th at the Waldorf Astoria in New York City.
